Health Care
Canopy Growth names Constellation Brands veteran as acting CFO
Image by Rex Medlen from Pixabay Shares of Canopy Growth Corporation (NYSE: CGC) gained over 2% on Tuesday after the…
Medtronic to announce Q4 results amidst pacemaker crisis
Medtronic (NYSE: MDT) is scheduled to report fourth-quarter 2019 financial results on Thursday, May 23, before the regular trading hours.…
Titan Pharmaceuticals posts wider-than-expected Q1 loss
Titan Pharmaceuticals (TTNP) reported a wider loss in the first quarter of 2019 due to lower revenues and higher operating…
Johnson & Johnson set to revitalize pharma biz; eyes ‘above-market’ growth
Drug maker Johnson & Johnson (NYSE: JNJ) is all set to embark on an extensive program to strengthen the product…
Aurora Cannabis’ net loss widens in Q3
Like last quarter, Canadian-based cannabis producer Aurora Cannabis (NYSE: ACB) delayed its third-quarter earnings today. The company reported a loss…
Aurinia Pharmaceuticals loss narrowed in Q1; AURORA trial on track
Aurinia Pharmaceuticals (NASDAQ:AUPH / TSX:AUP) narrowed its loss in the first quarter. Post the Q1 results, stock rose 2% in…
Tilray Q1 loss widens, meets estimates
Tilray (TLRY) reported a wider loss in the first quarter of 2019 due to higher operating costs and expenses. The…
Earnings: Agilent stock falls on Q2 earnings miss, weak guidance
Earnings of Agilent Technologies (Nasdaq: A), which manufactures instruments used in medical laboratories, increased in the second quarter but missed…
Solid Biosciences tumbles 38% to hit historic low
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results…
Aurora Cannabis Q3 earnings: What’s in the cards?
Canadian-based cannabis producer Aurora Cannabis (NYSE: ACB) is slated to report its third-quarter results on May 14 after the bell…
ESSA Pharma posts narrower loss in Q2
ESSA Pharma Inc. (EPIX) reported a narrower loss in the second quarter of 2019 helped by lower research and development…
Earnings: Ocular Therapeutix Q1 loss widens on higher R&D expenses
Biopharmaceutical firm Ocular Therapeutix (Nasdaq: OCUL) reported a wider net loss for the first quarter - despite an increase in…
Cronos Group starts off fiscal 2019 with a profit in Q1
In the first quarter of 2019, Cronos Group (NASDAQ: CRON) more-than-doubled its revenues to C$6.5 million, primarily driven by the launch…